Solomon Moshkevich, serving as President of Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), has liquidated a significant portion of his equity holdings, executing sales totaling $818,710 on July 1, 2026. This executive divestment unfolds against a backdrop of substantial equity appreciation for Natera, with the stock trading close to its 52-week peak of $288. The company has experienced a 79% increase in share value over the trailing twelve months. Despite this momentum, valuation analytics from InvestingPro indicate that Natera's current market price exceeds its calculated Fair Value, placing it within a cohort of stocks identified as overvalued.
The liquidation of Moshkevich's stake was structured under a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged stock transactions. This specific plan was instituted on November 26, 2024, and governed the execution of the recent sales. The total volume of the transaction comprised 3,000 shares of Natera common stock, executed across a spectrum of price points ranging from $267.185 to $274.06 per share.
A breakdown of the transaction details reveals distinct pricing tiers. The initial tranche involved 100 shares sold at a weighted average price of $267.185, with individual executions clustered tightly between $267.05 and $267.30. A subsequent block of 2,600 shares was liquidated at a weighted average price of $272.99, with transaction prices ranging from $272.74 to $273.00. The final segment of the sale consisted of 300 shares executed at $274.06 per share. Following the completion of these transactions, Moshkevich's direct ownership of Natera common stock stands at 134,643 shares.
Concurrent with the executive sale, Natera has advanced its clinical and regulatory footprint. The company announced the publication of data concerning its Signatera molecular residual disease test in the journal JAMA Oncology. This study encompassed 298 patients diagnosed with resected colorectal liver metastases and was presented at the 2026 European Society for Medical Oncology Gastrointestinal Congress. Furthermore, Natera has entered a partnership with Aveta Biomics to conduct a Phase 3 clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma. This trial will utilize Natera's Signatera testing to monitor molecular residual disease and assess treatment response.
Regulatory milestones also mark Natera's recent operational updates. The company secured approval from Japan's Pharmaceuticals and Medical Devices Agency for its Signatera test, establishing it as the first molecular residual disease test to receive such approval in the region. Natera intends to initiate a commercial launch of the test for colorectal cancer in Japan by the end of 2026.
Analyst sentiment regarding Natera reflects optimism regarding its growth trajectory. Bernstein SocGen Group resumed coverage with an outperform rating and a $310 price target, citing potential for increased volumes and reimbursement in minimal residual disease testing. Similarly, BTIG upgraded its price target to $270 while maintaining a Buy rating, following the inclusion of Natera's Signatera MRD test in NCCN guidelines for muscle-invasive bladder cancer.
Market data indicates Natera's stock closed at $283.80, representing a 1.60% gain, with after-hours trading showing a further 0.18% increase to $284.31. The stock's performance over the past year underscores significant investor interest in the molecular diagnostics sector, driven by clinical validation and regulatory expansion.